Survival Benefit Shown for Leukemia Patients Taking Rituxan

Drug Industry Daily
A A
Patients with chronic lymphocytic leukemia (CLL) who received Rituxan with chemotherapy lived considerably longer without disease progression than those treated with chemotherapy alone, Roche says.

To View This Article:

Login

Subscribe To Drug Industry Daily